Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Medical Marijuana for Sickle Cell Disease: Results of Two Years of Certification in an Adult Sickle Cell Center
source: American Society of Hematology
authors: Susanna A Curtis, Dana Lew, Jonathan Spodick, John D. Robertssummary/abstract:
Background: The hallmark of sickle cell disease (SCD) is pain, which can be both acute and chronic. Pain in patients with SCD leads to hospital admissions and diminishes quality of life. Pain in patients with SCD is primarily treated with opioid medications, which are often insufficient. In 2017 the Committee on the Health Effects of Marijuana of the National Academies of Science, Engineering, and Medicine reported that there is “conclusive or substantial evidence that cannabis or cannabinoids are effective for the treatment of chronic pain in adults”, but the report made no mention of chronic pain in patients with SCD.
Currently, 30 states and Washington D.C. have medical marijuana (MM) laws, and 5 states list SCD as a qualifying condition. SCD was added to the list of qualifying conditions in Connecticut in February 2016. Since then we have offered certification to patients in our program who make regular clinic visits and for whom we think MM will be safe. However, not all patients who are certified go on to complete the state regulatory paperwork and obtain MM. We hypothesized that those who had obtained MM would show an improvement in clinical outcomes compared to those patients who had been certified but not obtained MM.
Conclusion: Though there was no difference in admission rates between the two groups we examined prior to MM certification, and the only clinical difference was that those who obtained MM were more likely to be in the more severe genotype, those who obtained MM showed a decrease in admissions in the next 6 months compared to those who did not. We suggest that MM allowed patients to improve their pain relief and thereby reduce admission rates. This is consistent with data showing cannabinoid agonists improve pain in murine models of SCD. Larger, randomized and controlled studies of MM for pain in SCD should be conducted.organization: Yale University, USA; Sackler School of Medicine, Israel
Patients frequently turning to cannabis to treat symptoms of sickle cell diseaseMedical cannabis use is relatively commo...
Researchers raise funds for phase 1 trial to test medical cannabis in sickle cell diseaseThe Sickle Cell Foundation of Georgia ...
Medical Marijuana Certification for Patients With Sickle Cell Disease: A Report of a Single Center ExperienceMore than one-third of adults with sickl...
Use of Marijuana in Patients with Sickle Cell Disease Increased the Frequency of Hospitalization for Acute Painful V...Introduction: Recently, there has been g...
Marijuana use common in sickle cell patients, highlighting need for more research, study showsMany sickle cell disease (SCD)...
Sickle Cell Patients are Innocent Victims of the Opioid Epidemic: Samir K. Ballas, MDhttps://www.youtube.com/watch?v=BOhY_gJo...
Public Meeting on Patient-Focused Drug Development for Chronic PainMeeting Information: On July 9, 2018, F...
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.